One of the problems of analysing patient outcomes is discriminating clearly between different diseases and variants.That’s the case for type 1 and 2 diabetes – different syndromes, but not always analysed separately in the health data.
This report, by three employees of Eli Lilly and three consultants, provides a systematic review of the literature to identify and compare published “health state utility” values for adults with type 1 diabetes, using different types of questionnaires to determine patient-reported health-related quality of life.
The study concludes that there is a lack of utility data for certain complications of type 1 diabetes.The tendency to use a combination of outcome measurements for type 1 and type 2 diabetes can result in inaccurate results, because it does not adequately account for the differences in these two conditions and the affected populations.
“Evaluating health-related quality of life in type 1 diabetes: a systematic literature review of utilities for adults with type 1 diabetes.” Published 7 October 2016 in Clinicoecon Outcomes Results.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
